PE Completes $7 Million Placement of New Shares

30 November 2018

PACIFIC EDGE COMPLETES $7 MILLION PLACEMENT OF NEW SHARES

Pacific Edge Limited (NZX: PEB) (Pacific Edge) advises that it has completed a placement of $7m of new shares
under its capital raising announced on 29 November 2018 (Placement).

Chair of Pacific Edge, Chris Gallaher, said: “We are pleased to have completed the first phase of our capital raising
which will provide funding to progress our commercial objectives and become cash flow positive as soon as
possible.”

Trading of Pacific Edge on the NZX is expected to resume at market open. The new shares under the Placement
are expected to be allotted and commence trading on the NZX Main Board on Wednesday 5 December 2018.

All New Zealand resident shareholders of Pacific Edge will have the opportunity to subscribe for additional Pacific
Edge shares at no greater than the placement price ($0.35) in due course. The full terms and conditions of the
Share Purchase Plan (SPP) will be contained in an offer document which will be distributed to all eligible
shareholders after the proposed record date.

Share Purchase Plan Timetable
Record Date of SPP 7 December
Opening Date for SPP 10 December
Closing Date for SPP 25 January 2019
Allotment and Settlement of SPP shares 31 January 2019

All dates and times are indicative only and subject to change.

- ENDS -

David Darling
Chief Executive Officer
Pacific Edge Ltd

Cell: +64 21 797 981
Ph: +64 3 4795 800

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is
developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central
laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre
clinical studies.

Pacific Edge has three proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and
better detection and management of urothelial cancer. Cxbladder Detect and Cxbladder Triage are available through the
company’s dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Monitor
launched in New Zealand in December 2015 and is anticipated being available in the US in 2016.

30 November 2018

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and
the USA as a Laboratory Developed Test (LDT) from the company’s CLIA certified laboratories. Cxbladder Detect provides
clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic
test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient specific clinical factors
to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires life-
long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose
Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is
designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of
recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from
a small quantity of a patient’s urine, with patient characteristics for the identification of patients who are likely to have
aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria
and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying
patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment
options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.